珠穆朗玛峰药物报告,珠穆朗玛峰(Ever001)的早期试验成功,这是治疗肾脏自免疫疾病的一种可能的新疗法。 Everest Medicines reports successful early trials for EVER001, a potential new treatment for autoimmune kidney disease.

Everest Medicines 报告了其针对 EVER001 的 1b/2a 期试验的可喜结果，是一种旨在治疗原发性膜性肾病 （pMN） 的新药，这种疾病影响了全球超过 1000 万人。 Everest Medicines has reported promising results from its Phase 1b/2a trial for EVER001, a new drug aimed at treating primary membranous nephropathy (pMN), a condition affecting over 10 million people worldwide. 试验显示自身抗体和蛋白尿显著减少,没有严重的副作用. The trial showed significant reductions in autoantibodies and proteinuria, with no serious side effects. Ever001可成为治疗PMN和其他自发性肾脏疾病的一种新选择。 EVER001 could become a new treatment option for pMN and other autoimmune kidney diseases.